Today's Top Stories


Hot Topics


Comment & Analysis »

GlobalData Healthcare

Nabriva’s first-in-class antibiotic lefamulin aces key Phase III test

On September 18, Nabriva Therapeutics announced positive topline results for its investigational antibiotic, lefamulin (formerly BC-3781), which is currently in Phase III of clinical...

Nabriva’s first-in-class antibiotic lefamulin aces key Phase III test
GlobalData Healthcare

Failure of first lampalizumab Phase III study could delay availability

Failure of first lampalizumab Phase III study could delay availability
GlobalData Healthcare

ESMO 2017: PD-L1 as an Evolving Narrative in Patient Selection and Drug Resistance – Part 2

ESMO 2017: PD-L1 as an Evolving Narrative in Patient Selection and Drug Resistance – Part 2
GlobalData Healthcare

ESMO 2017: PD-L1 as an Evolving Narrative in Patient Selection and Drug Resistance – Part 1

ESMO 2017: PD-L1 as an Evolving Narrative in Patient Selection and Drug Resistance – Part 1
GlobalData Healthcare

ESMO 2017: Adjuvant Opdivo (Nivolumab) superior to Yervoy (Ipilimumab) in surgically resected stage III/IV melanoma

ESMO 2017: Adjuvant Opdivo (Nivolumab) superior to Yervoy (Ipilimumab) in surgically resected stage III/IV melanoma

Company Releases »

Reasons to Replace Your Viscometer with a Rheometer

Malvern Instruments
Reasons to Replace Your Viscometer with a Rheometer

Application: Operating Reactor Systems for Process Research and Development

SYSTAG Systems Technik
Application: Operating Reactor Systems for Process Research and Development

Characterisation Information of Critical Excipients for Sourcing Critical Raw Materials

Pfanstiehl Characterisation Information of Critical Excipients for Sourcing Critical Raw Materials

Pharmaceutical Regulatory Consultant and FDA Regulatory Strategist

Pharmaceutical Development Group
Pharmaceutical Regulatory Consultant and FDA Regulatory Strategist

Research Models to Evaluate Drug Candidate Efficacy

Pharmatest Services Research Models to Evaluate Drug Candidate Efficacy

Drugdevelopment Insights »

Drugdevelopment Industry Reports »

Report: Immuno-Oncology to evolve as promising cancer treatment alternative

Report: Immuno-Oncology to evolve as promising cancer treatment alternative

Osteoarthritis is significantly underdiagnosed in the US

Osteoarthritis is significantly underdiagnosed in the US

Immuno-Oncology drugs lead Japanese clinical trials, 2012-2016

Immuno-Oncology drugs lead Japanese clinical trials, 2012-2016

PAH registries may underestimate patient size by as much as sevenfold

PAH registries may underestimate patient size by as much as sevenfold








cachename:HomePagecachekey:rd-1665407042_1729060782_rd-488908060_1460672566_ap1460672566_1729060782_1903286115